GMAB Stock Forecast & Price Target

Genmab is well positioned by a diversified portfolio of marketed assets and late-stage pipeline programs that can cushion the looming Darzalex patent cliff in 2029-31, while still delivering steady royalty and revenue growth from 8 approved drugs and multiple partnerships. The standout drivers are Epkinly, Rina-S, and petosemtamab: Epkinly’s Phase 3 DLBCL-2 readout reduced progression/death risk by 51%, Rina-S produced exceptional Phase 3 RAINFOL-02 hazard ratios of 0.29 for PFS and 0.43 for OS, and petosemtamab showed 63% ORR and 28.2 months mOS in 1L HNSCC, de-risking upcoming pivotal data. These results, plus capital-efficient collaborations in CRC and broad activity across tumor types, support a favorable growth outlook.

Genmab is facing a risk profile that is materially skewed to the downside because its outlook depends on sustained commercial execution from a concentrated portfolio while exposing it to R&D, regulatory, legal, and commercialization setbacks. The company’s dependence on Darzalex as its leading product, along with partnered assets such as Tepezza, Kesimpta, Rybrevant, Tivdak, and Epkinly, increases vulnerability to lower-than-expected sales and partner-related execution issues, while emerging competitors could pressure future growth. In addition, financing risks tied to the Merus acquisition and associated debt financing raise balance-sheet concerns, making the stock less attractive if pipeline advances fail to offset these fundamental uncertainties.